Home Cell Cycle Wee1

Wee1

Other Cell Cycle Related Inhibitors

CDK ROCK Aurora Kinase Chk PLK APC MPS1 Rho Myc DYRK
Cat.No. Product Name Information Product Use Citations Product Validations
S1525 Adavosertib (AZD1775, MK-1775) Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.
Cancer Cell, 2025, 43(8):1530-1548.e9
Nat Cancer, 2025, 10.1038/s43018-025-00960-z
Cell Rep Med, 2025, S2666-3791(25)00102-8
Verified customer review of Adavosertib (AZD1775, MK-1775)
S8148 PD0166285 PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). This compound is also a novel G2 checkpoint abrogator. It induces apoptosis.
iScience, 2025, 28(5):112292
Signal Transduct Target Ther, 2024, 9(1):181.
Nat Commun, 2024, 15(1):2089
S9778 Debio 0123 WEE1-IN-5 (Debio 0123) is a potent Wee1 inhibitor that inhibits phospho-CDC2 and abrogates the G2 check point.
J Clin Invest, 2025, 135(11)e188165
medRxiv, 2024, 2023.05.17.23290140
E1000 Azenosertib (Zn-C3) Azenosertib (Zn-C3) is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.
bioRxiv, 2025, 2025.05.28.656693
medRxiv, 2024, 2023.05.17.23290140
E4737 Potrasertib Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.
E1175 RP-6306 (lunresertib) lunresertib (RP-6306) is a Protein Kinase, Membrane Associated Tyrosine/Threonine 1 (PKMYT1) inhibitor, which can be used for the research of cancer.
Cell Rep, 2025, 44(8):116019
BMC Cancer, 2024, 24(1):1333

Signaling Pathway Map